Supplementary Materials – Maspero JF, et al. Clinical Efficacy Among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease:

Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies

## Supplementary Figure 1 Flowchart of patient disposition

## Coexisting asthma Clinical features of obstructive lung disease Clinical features of obstructive lung disease (broad definition) (narrow definition) 170 assigned to placebo q2w 258 assigned to dupilumab q2w 57 assigned to placebo q2w 74 assigned to dupilumab q2w 48 assigned to placebo q2w 67 assigned to dupilumab q2w 23 discontinued treatment 1 randomized but not treated 5 discontinued treatment 5 discontinued treatment 4 discontinued treatment 5 discontinued treatment before Week 24 8 discontinued treatment before Week 24 before Week 24 before Week 24 before Week 24 10 for adverse events before Week 24 2 for adverse events 3 for adverse events 1 for adverse events 3 for adverse events 4 for lack of efficacy 2 for lack of efficacy 0 for lack of efficacy 2 for lack of efficacy 0 for lack of efficacy 6 for adverse events 0 for lack of efficacy 0 for poor compliance 1 for poor compliance 0 for poor compliance 0 for poor compliance 0 for poor compliance 2 for other reasons 1 for other reasons 2 for other reasons 8 for other reasons 0 for poor compliance 1 for other reasons 2 for other reasons 13 had SCS or surgery → 10 had SCS or surgery → 10 had SCS or surgery → 55 had SCS or surgery 26 had SCS or surgery 9 had SCS or surgery 249 completed 24 weeks 147 completed 24 weeks 52 completed 24 weeks 69 completed 24 weeks 44 completed 24 weeks 62 completed 24 weeks

Abbreviations: SCS, systemic corticosteroids; q2w, every 2 weeks

Supplementary Materials – Maspero JF, et al. Clinical Efficacy Among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies

**Supplementary Table 1** Effect of dupilumab on lung function as assessed by pre-bronchodilator FEV<sub>1</sub> and FEV<sub>1</sub>/FVC in patients with CRSwNP with asthma and in patients with CRSwNP, asthma, and clinical features of obstructive lung disease

			Asthma and clinical features of obstructive lung disease				
	Asthma		(Broad Definition)		(Narrow Definition)		
-	Placebo (n = 170)	Dupilumab (n = 258)	Placebo (n = 40)	Dupilumab (n = 50)	Placebo (n = 31)	Dupilumab (n = 43)	
FEV <sub>1</sub>							
Baseline, n	169	258	40	50	31	43	
FEV <sub>1</sub> , mean (SD), L	2.62 (0.83)	2.61 (0.92)	2.45 (0.76)	2.43 (0.92)	2.36 (0.76)	2.33 (0.79)	
Week 16, n	166	253	40	49	31	42	
FEV <sub>1</sub> , mean (SD), L	2.57 (0.81)	2.76 (0.86)	2.35 (0.83)	2.69 (0.83)	2.28 (0.88)	2.67 (0.87)	
LS mean change from baseline (SE)	-0.07 (0.03)	0.15 (0.03)	-0.07 (0.08)	0.31 (0.08)	-0.04 (0.10)	0.36 (0.11)	
LS mean difference vs placebo (95% CI) Nominal p vs placebo	0.22 (0.15, 0.29) <0.0001		0.38 (0.17, 0.59) 0.0004		0.40 (0.20, 0.61) 0.0001		
Week 24, n	163	252	40	49	31	42	
FEV <sub>1</sub> , mean (SD), L	2.57 (0.80)	2.76 (0.91)	2.40 (0.83)	2.66 (0.81)	2.34 (0.88)	2.65 (0.84)	
LS mean change from baseline (SE)	-0.07 (0.04)	0.14 (0.03)	-0.03 (0.08)	0.27 (0.08)	-0.02 (0.09)	0.28 (0.10)	
LS mean difference vs placebo (95% CI) Nominal p vs placebo	0.21 (0.13, 0.29) <0.0001		0.29 (0.09, 0.49) 0.0039		0.30 (0.11, 0.49) 0.0016		
FEV <sub>1</sub> /FVC							
Baseline, n	169	258	40	50	31	43	
FEV <sub>1</sub> /FVC, mean (SD)	0.72 (0.10)	0.71 (0.10)	0.68 (0.10)	0.65 (0.09)	0.64 (0.09)	0.62 (0.07)	
Week 16, n	166	253	40	49	31	42	
FEV <sub>1</sub> /FVC, mean (SD)	0.72 (0.10)	0.73 (0.09)	0.67 (0.12)	0.69 (0.08)	0.64 (0.12)	0.68 (0.08)	

Supplementary Materials – Maspero JF, et al. Clinical Efficacy Among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease:

Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies

LS mean change from baseline (SE)	<0.01 (0.01)	0.02 (0.01)	<0.01 (0.01)	0.05 (0.01)	0.03 (0.02)	0.09 (0.02)
LS mean difference vs placebo (95% CI)	0.03 (0.01, 0.04)		0.05 (0.02, 0.08)		0.06 (0.03, 0.10)	
Nominal p vs placebo	<0.0001		0.0024		0.0003	
Week 24, n	163	252	40	49	31	42
FEV <sub>1</sub> /FVC, mean (SD)	0.72 (0.10)	0.74 (0.09)	0.67 (0.12)	0.69 (0.07)	0.65 (0.12)	0.67 (0.06)
LS mean change from baseline (SE)	<0.01 (0.01)	0.02 (0.01)	<0.01 (0.01)	0.04 (0.01)	0.02 (0.02)	0.06 (0.02)
LS mean difference vs placebo (95% CI)	0.02 (0.01, 0.04)		0.04 (0.01, 0.07)		0.04 (0.01, 0.08)	
Nominal p vs placebo	0.0014		0.0235		0.0152	

Notes: Patients with baseline and post-baseline FEV<sub>1</sub> and FVC assessments at either Week 16 or Week 24 were included in the analysis.

**Abbreviations:** CI, confidence interval; CRSwNP, chronic rhinosinusitis with nasal polyps; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; LS, least squares; SD, standard deviation; SE, standard error.